We can’t show the full text here under this license. Use the link below to read it at the source.
Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program
Body weight loss with tirzepatide in women at different reproductive stages
AI simplified
Abstract
Tirzepatide treatment resulted in 26% body weight reduction in premenopausal women compared to 2% with placebo.
- Significant body weight reductions were observed across all reproductive stages with tirzepatide: 26% in premenopause, 23% in perimenopause, and 23% in postmenopause.
- Waist circumference reductions were also significant with tirzepatide, showing decreases of 22 cm in premenopause, 20 cm in perimenopause, and 20 cm in postmenopause.
- 97% to 98% of participants on tirzepatide achieved at least a 5% reduction in body weight, compared to only 29% to 33% with placebo.
- 30% to 52% of women with baseline BMI < 35 kg/m² reached a waist-to-height ratio of ≤0.49, indicating low central adiposity, with tirzepatide.
- Similar outcomes were reported in the additional SURMOUNT-3 and -4 studies.
AI simplified
Key numbers
24% to 26%
Weight Reduction Increase
Weight loss percentage with vs. placebo in SURMOUNT-1.
20 to 22 cm
Reduction
Reduction in with vs. placebo.
97% to 98%
Achieved Weight Loss Threshold
Proportion of participants achieving ≥5% weight loss with vs. placebo.